Lummy(SZ:300006)2025-09-25 11:42Group 1: Shareholder and Equity Transfer - The company is monitoring the equity transfer plan of its major shareholder, Zhongheng Group, and will disclose any progress according to relevant regulations [2][3][6]. - As of September 19, 2025, the number of shareholders is 35,528 [6][20]. Group 2: Product Development and Clinical Trials - The company’s subsidiary, Sichuan Yingrui, is advancing the clinical phase II trial of its nanocarbon iron injection (CNSI-Fe) [5][18]. - The company is focusing on the development of its flagship product, Kanalin, and has completed the technical design for its overseas expansion, currently in preclinical animal testing [7][22]. - The company is actively pursuing innovative drug development, including personalized cancer vaccines and treatments for liver cirrhosis, with ongoing clinical trials [8][26]. Group 3: Financial Performance and Future Plans - The company has no current plans for stock buybacks, and any dividend plans for 2025 will depend on the actual performance of the company [4][27]. - The company is committed to enhancing operational efficiency and market competitiveness through cost control and management improvements [4][9].